# US 2011/0086840 A1 · N-7 substituted purine and pyrazolopyrimine compounds, compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0086840 A1
- Document ID: US20110086840A1
- Status: Published application
- Kind: A1
- Application number: 12/943,225
- Filed: 2010-11-10
- Published: 2011-04-14
- Earliest claimed: 2009-11-12
- Assignees: Genentech, Inc.
- Inventors: Zhonghua Pei; Joseph P. Lyssikatos; Wendy Lee; Kirk D. Robarge
- Web page: https://patentgrep.com/patent/US20110086840A1

## CPC

- C07D 473/34: attached in position 6, e.g. adenine
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07D 487/04: Ortho-condensed systems
- C07D 519/00: Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of Formula I: wherein R1, R2, R3, A1, A2, A3, A4, Y1 and Y2 and D have the meaning described herein. The present invention also relates to pharmaceutical compositions comprising such compounds and therapeutic uses thereof.

## Claims

### Claim 1

A compound of Formula I:
wherein Y1 and Y2 is each independently N or C(R1), but Y1 and Y2 are not both N or are not both C(R1), wherein R1 is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 heteroalkyl, 6- to 10-membered aryl, 5- to 9-membered heteroaryl, 3- to 12-membered heterocycloalkyl, 3- to 12-membered cycloalkyl, wherein R1 is substituted with from 0 to 5 RR1 substituents selected from the group consisting of halogen, F, Cl, Br, I, —NRaRb, —SRa, —ORa, —C(O)ORa, —C(O)NRaRb, —C(O)Ra, —NRaC(O)Rb, —OC(O)Rc, —NRaC(O)NRaRb, —OC(O)NRaRb, —NRaS(O)2NRaRb, —S(O)2Ra, —S(O)2NRaRb, —Rc, —NO2, —N3, ═O, —CN, Rc1, —X1—NRaRb, —X1—SRa, —X1—ORa, —X1—C(O)ORa, —X1—C(O)NRaRb, —X1—C(O)Ra, —X1—NRaC(O)Rb, —X1—OC(O)Ra, —X1—NRaC(O)NRaRb, —X1—OC(O)NRaRb, —X1—NRaS(O)2NRaRb, —X1—S(O)2Ra, —X1—S(O)2NRaRb, —X1—NO2, —X1—N3, —X1—CN, and X1-Rc1; wherein Ra and Rb are each independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 heteroalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C2-7 heterocycloalkyl, phenyl and —(CH2)1-4-phenyl, optionally Ra and Rb, when attached to the same nitrogen atom are combined to form a 3- to 6-membered heterocyclic ring comprising 1 to 2 heteroatoms selected from N, O and S; Rc is selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C2-7 heterocycloalkyl, phenyl and —(CH2)1-4-phenyl; X1 is selected from the group consisting of C1-4 alkylene, C2-4 alkenylene and C2-4 alkynylene; and Rc1 is selected from the group consisting of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-imidazolyl, 2-indolyl, 1-naphthyl, 2-naphthyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 2-furanyl and 3-furanyl, and wherein Rc1 is substituted with from 0 to 3 substituents selected from F, Cl, Br, I, —NRaRb, —SRa, —ORa, —S(O)2Ra, —S(O)2NRaRb, —NO2, —N3, ═O, —CN, pyridyl, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C1-6 heteroalkyl;
R2 is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 heteroalkyl, -L-C6-10 aryl, -L-C1-9 heteroaryl, -L-C3-12 cycloalkyl and -L-C2-12 heterocycloalkyl, wherein L is selected from C1-6 alkylene, C2-6 alkenylene, C2-6 alkynylene and C1-6 heteroalkylene, and wherein R2 is substituted with from 0 to 5 RR2 substituents selected from the group consisting of halogen, F, Cl, Br, I, —NRdRe, —SRd, —ORd, —C(O)ORd, —C(O)NRdRe, —C(O)Rd, —NRdC(O)Re, —OC(O)Rf, —NRdC(O)NRdRe, —OC(O)NRdRe, —NRdS(O)2NRdRe, —S(O)2Rd, —S(O)2NRdRe, —Rf, —NO2, —N3, ═O, —CN, —X2—NRdRe, —X2—SRd, —X2—ORd, —X2—C(O)ORd, —X2—C(O)NRdRe, —X2—C(O)Rd, —X2—NRdC(O)Re, —X2—OC(O)Rd, —X2—NRdC(O)NRdRe, —X2—OC(O)NRdRe, —X2—NRdS(O)2NRdRe, —X2—S(O)2Rd, —X2—S(O)2NRdRe, —X2—NO2, —X2—N3 and —X2—CN;
wherein Rd and Re are each independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 heteroalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C2-7 heterocycloalkyl, phenyl and —(CH2)1-4-phenyl, optionally Rd and Re, when attached to the same nitrogen atom are combined to form a 3- to 6-membered heterocyclic ring comprising 1 to 2 heteroatoms selected from N, O and S; Rf is selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkyllyl, C3-7 cycloalkyl, C2-7 heterocycloalkyl, phenyl and —(CH2)1-4-phenyl; and X2 is selected from the group consisting of C1-4 alkylene, C2-4 alkenylene and C2-4 alkynylene;
R3 is a 5- to 12-membered monocyclic or bridged heterocycloalkyl ring, wherein the R3 group is substituted with from 0 to 3 RR3 substituents selected from the group consisting of —C(O)ORg, —C(O)NRgRh, —NRgRh, —ORg, —SRg, —S(O)2Ri, —S(O)Ri, —Ri, halogen, F, Cl, Br, I, —NO2, —CN and —N3, wherein Rg and Rh are each independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 heteroalkyl, C2-6 alkenyl and C3-6 cycloalkyl, wherein optionally Rg and Rh, together with the nitrogen atom to which each is attached, are combined to form a 3- to 6-membered heterocyclic ring comprising 1 to 2 heteroatoms selected from N, O and S, and Ri is selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C3-6 cycloalkyl; and when R3 is a monocyclic heterocycloalkyl ring then any two RR3 groups attached to the same atom of R3 is optionally combined to form at 3- to 7-membered carbocyclic or 3- to 7-membered heterocyclic ring comprising 1 to 2 atoms selected from N, O and S as ring vertices;
A1, A2, A3 and A4 are each a member independently selected from N, C(RA) or C(H), wherein at least three of A1, A2, A3 and A4 is each independently C(H) or C(RA), wherein RA at each occurrence is independently selected from the group consisting of F, Cl, Br, I, —NO2, —CN, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, or any two RA groups attached to adjacent atoms are optionally combined to form a C2-6 heterocyclic ring comprising from 1 to 2 heteroatoms selected from N, O and S as ring vertices, C3-7 cycloalkyl ring, a C1-5 heteroaryl ring comprising from 1 to 4 heteroatoms selected from N, O and S as ring vertices, or phenyl ring; and
D is a member selected from the group consisting of —NR4C(O)NR5R6, —NR5R6, —C(O)NR5R6, —OC(O)OR5, —OC(O)NR5R6, —NR4C(═N—CN)NR5R6, —NR4C(═N—OR5)NR5R6, —NR4C(═N—NR5)NR5R6, —NR4C(O)R5, —NR4C(O)OR5, —NR4S(O)2NR5R6 and —NR4S(O)2R5, wherein R4 is selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl and C2-6 alkenyl; R5 and R6 are each independently selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-10 cycloalkyl, C2-10 heterocycloalkyl, C6-10 aryl and C1-9 heteroaryl, and R5 and R6, when attached to the same nitrogen atom, are optionally combined to form a 5- to 7-membered heterocyclic or a 5- to 9-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from N, O and S as ring vertices and substituted with 0-3 RD substituents; and wherein R4, R5 and R6 are further substituted with from 0 to 3 RD substituents, wherein RD is independently selected from the group consisting of halogen, F, Cl, Br, I, —NO2, —CN, —NRjRk, —ORj, —SRj, —C(O)ORj, —C(O)NRjRk, —NRjC(O)Rk, —NRjC(O)ORm, —X3—NRjRk, —X3—C(O)ORk, —X3—C(O)NRjRk, —X3—NRjC(O)Rk, —X3—NRjC(O)ORk, —X3—CN, —X3—NO2, —S(O)Rm, —S(O)2Rm, ═O, and —Rm; wherein Rj and Rk is selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 heteroalkyl, C3-7 cycloalkyl, C3-7 heterocycloalkyl, C6-10 aryl, C1-9 heteroaryl; and Rm, at each occurrence, is independently selected from C1-6 alkyl, C1-6 haloalkyl, C3-7 cycloalkyl, C3-7 heterocycloalkyl, C6-10 aryl and C1-9 heteroaryl; X3 is selected from the group consisting of C1-4 alkylene, C2-4 alkenylene and C2-4 alkynylene; and wherein D and a RA substituent attached to an atom that is adjacent to the atom to which D is attached are optionally combined to form an optionally substituted 5- to 6-membered heterocyclic or heteroaryl ring substituted with from 0 to 4 RD substituents.

### Claim 2 (depends on 1)

The compound of claim 1, wherein said compound is of Formula I-A

### Claim 3 (depends on 1)

The compound of claim 1, wherein said compound is of Formula I-B:

### Claim 4 (depends on 1)

The compound of claim 1, wherein R3 is selected from the group consisting of morpholin-4-yl, 3,4-dihydro-2H-pyran-4-yl, 3,6-dihydro-2H-pyran-4-yl, tetrahydro-2H-pyran-4-yl, 1,4-oxazepan-4-yl, 2-oxa-5-azabicyclo[2.2.1]heptan-5-yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, piperidin-1-yl, and 8-oxa-3-azabicyclo[3.2.1]octan-3-yl, wherein the R3 group is substituted with from 0 to 3 RR3 substituents selected from the group consisting of —C(O)ORg, —C(O)NRgRh, —NRgRh, —ORg, —SRg, —S(O)2Ri, —S(O)Ri, —Ri, halogen, F, Cl, Br, I, —NO2, —CN and —N3, wherein Rg and Rh are each independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 heteroalkyl, C2-6 alkenyl and C3-6 cycloalkyl, wherein optionally Rg and Rh, together with the nitrogen atom to which each is attached, are combined to form a 3- to 6-membered heterocyclic ring comprising 1 to 2 heteroatoms selected from N, O and S, and R3 is selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C3-6 cycloalkyl; and if R3 is a monocyclic heterocycloalkyl ring then any two RR3 groups attached to the same atom of R3 is optionally combined to form at 3- to 7-membered carbocyclic or 3- to 7-membered heterocyclic ring comprising 1 to 2 atoms selected from N, O and S as ring vertices.

### Claim 5 (depends on 4)

The compound of claim 4, wherein R3 is substituted with from 0 to 2 RR3 substituents selected from —NRgRh, —ORg, and Ri, and when R3 is a monocyclic heterocycloalkyl ring then any two RR3 groups attached to the same atom of R3 is optionally combined to form at 3- to 7-membered carbocyclic or 3- to 7-membered heterocyclic ring comprising 1 to 2 atoms selected from N, O and S as ring vertices.

### Claim 6 (depends on 4)

The compound of claim 4, wherein R3 is selected from the group consisting of morpholin-4-yl, 3(R)-methyl-morpholin-4-yl, 3(S)-methyl-morpholin-4-yl, 3(R)-ethyl-morpholin-4-yl, 3(S)-ethyl-morpholin-4-yl, 3(R)-isopropyl-morpholin-4-yl, 3(S)-isopropyl-morpholin-4-yl, 3,3-dimethyl-morpholin-4-yl, 3,4-dihydro-2H-pyran-4-yl, 3,6-dihydro-2H-pyran-4-yl, tetrahydro-2H-pyran-4-yl, 1,4-oxazepan-4-yl, piperidin-1-yl, 2-oxa-5-azabicyclo[2.2.1]heptan-5-yl, 3-oxa-8-azabicyclo[3.2.1]octan-8-yl, 4-methoxy-piperidin-1-yl and 8-oxa-3-azabicyclo[3.2.1]octan-3-yl.

### Claim 7 (depends on 1)

The compound of claim 1, wherein D is selected from the group consisting of —NR4C(O)NR5R6, —NR5R6, —C(O)NR5R6, —NR4C(═N—CN)NR5R6, —NR4C(O)R5, —NR4C(O)OR5, —NR4S(O)2NR5R6 and —NR4S(O)2R5.

### Claim 8 (depends on 7)

The compound of claim 7, wherein D is —NR4C(O)NR5R6 or —NR5R6, wherein R4 is hydrogen, R5 and R6 are each independently an optionally substituted group selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 heteroalkyl, haloalkyl, C3-7 cycloalkyl, C2-7 heterocycloalkyl, C6-10 aryl, and C1-9 heteroaryl, and R5 and R6, when attached to the same nitrogen atom, are optionally combined to form an a 5- to 7-heterocyclic ring or a 5- to 9-membered heteroaryl ring comprising 1 to 3 heteroatoms selected from N, O and S as ring vertices and is substituted with from 0 to 3 RD substituents.

### Claim 9 (depends on 8)

The compound of claim 8, wherein D is —NR5R6, wherein R5 is hydrogen or C1-3 alkyl, and R6 is an optionally substituted C6-10 aryl, C1-9 heteroaryl or C3-7 heterocycloalkyl.

### Claim 10 (depends on 9)

The compound of claim 9, wherein D is —NR5R6, wherein R5 is hydrogen or C1-3 alkyl, and R6 is an optionally substituted C3-7 heterocycloalkyl selected from the group consisting of:
wherein a hydrogen atom attached to one or more nitrogen or carbon ring vertices in the C3-7 heterocycloalkyl ring is optionally replaced with a RD substituent selected from the group consisting of F, Cl, Br, I, —NRjRk, —ORj and Rs.

### Claim 11 (depends on 10)

The compound of claim 10, wherein D is selected from the group consisting of

### Claim 12 (depends on 8)

The compound of claim 8, wherein D is —NR5R6, wherein R5 and R6 are combined to form an optionally substituted 5-membered heteroaryl ring selected from the group consisting of pyrrolyl, pyrazolyl, imidazolyl and triazolyl.

### Claim 13 (depends on 8)

The compound of claim 8 wherein D is —NR4C(O)NR5R6, wherein R4 is hydrogen; R5 and R6 are each independently an optionally substituted group selected from the group consisting of hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 heteroalkyl, C3-7 cycloalkyl, C3-7 heterocycloalkyl, a 5- to 6-membered heteroaryl, and optionally substituted phenyl.

### Claim 14 (depends on 13)

The compound of claim 13, wherein one of R5 and R6 is hydrogen.

### Claim 15 (depends on 14)

The compound of claim 14, wherein R4 and R5 are each hydrogen and R6 is an optionally substituted group selected from C1-6 alkyl and C1-6 haloalkyl.

### Claim 16 (depends on 15)

The compound of claim 15, wherein R6 is selected from the group consisting of

### Claim 17 (depends on 16)

The compound of claim 16, wherein R6 is ethyl.

### Claim 18 (depends on 13)

The compound of claim 13, wherein R4 is hydrogen and R5 is hydrogen or C1-3 alkyl and R6 is an optionally substituted group selected from the group consisting of optionally substituted isoxazol-3-yl, isoxazol-4-yl isoxazol-5-yl, oxazol-2-yl, oxazol-4-yl, oxazol-5-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, 1,2,3-oxadiazol-4-yl, 1,2,3-oxadiazol-5-yl, 1,3,4-oxadiazol-2-yl, 1,3,4-oxadiazol-5-yl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 5-pyridyl, cyclobutyl, cyclopentyl, cyclohexyl, 2-oxepanyl, 3-oxepanyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl and phenyl.

### Claim 19 (depends on 18)

The compound of claim 18, wherein R6 is independently substituted with from 0 to 3 substituents selected from F, Cl, Br, I, —CN, —NRjRk and —ORj.

### Claim 20 (depends on 18)

The compound of claim 18, wherein R6 is selected from the group consisting of

### Claim 21 (depends on 18)

The compound of claim 18, wherein R6 is selected from the group set forth in FIG. 2.

### Claim 22 (depends on 1)

The compound of claim 1, wherein R1 is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 heteroalkyl, phenyl, 5- to 6-membered heteroaryl, 3- to 7-membered heterocycloalkyl, 3- to 7-membered cycloalkyl, wherein R1 is substituted with from 0 to 5 RR1 substituents selected from the group consisting of halogen, F, Cl, Br, I, —NRaRb, —SRa, —ORa, —C(O)ORa, —C(O)NRaRb, —C(O)Ra, —NRaC(O)Rb, —OC(O)Rc, —NRaC(O)NRaRb, —OC(O)NRaRb, —NRaS(O)2NRaRb, —S(O)2Ra, —S(O)2NRaRb, —Rc, —NO2, —N3, ═O, —CN, Rc1, —X1—NRaRb, —X1—SRa, —X1—ORa, —X1—C(O)ORa, —X1—C(O)NRaRb, —X1—C(O)Ra, —X1—NRaC(O)Rb, —X1—OC(O)Ra, —X1—NRaC(O)NRaRb, —X1—OC(O)NRaRb, —X1—NRaS(O)2NRaRb, —X1—S(O)2Ra, —X1—S(O)2NRaRb, —X1—NO2, —X1—N3, —X1—CN, and X1—Rc1; wherein Ra and Rb are each independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 heteroalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C2-7 heterocycloalkyl, phenyl and —(CH2)1-4-phenyl, optionally Ra and Rb, when attached to the same nitrogen atom are combined to form a 3- to 6-membered heterocyclic ring comprising 1 to 2 heteroatoms selected from N, O and S; Rc is selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C2-7 heterocycloalkyl, phenyl and —(CH2)1-4-phenyl; X1 is selected from the group consisting of C1-4 alkylene, C2-4 alkenylene and C2-4 alkynylene, and Rc1 is selected from the group consisting of phenyl, 2-pyridyl, 3-pyridyl, 4-pyridyl, 2-imidazolyl, 2-indolyl, 1-naphthyl, 2-naphthyl, 2-thienyl, 3-thienyl, 2-pyrrolyl, 2-furanyl and 3-furanyl, and wherein Rc1 is substituted with from 0 to 3 substituents selected from F, Cl, Br, I, —NRaRb, —SRa, —ORa, —S(O)2Ra, —S(O)2NRaRb, —NO2, —N3, ═O, —CN, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C1-6 heteroalkyl; and R2 is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl and C1-6 heteroalkyl, and wherein R2 is substituted with from 0 to 3 RR2 substituents selected from the group consisting of halogen, F, Cl, Br, I, —NRdRe, —SRd, —ORd, —C(O)ORd, —C(O)NRdRe, —C(O)Rd, —NRdC(O)Re, —OC(O)Rf, —NRdC(O)NRdRe, —OC(O)NRdRe, —NRdS(O)2NRdRe, —S(O)2Rd, —S(O)2NRdRe, —Rf, —NO2, —N3, ═O and —CN; wherein Rd and Re are each independently selected from hydrogen, C1-6 alkyl, C1-6 haloalkyl, C1-6 heteroalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C2-7 heterocycloalkyl, phenyl and —(CH2)1-4-phenyl, optionally Rd and Re, when attached to the same nitrogen atom are combined to form a 3- to 6-membered heterocyclic ring comprising 1 to 2 heteroatoms selected from N, O and S; and Rf is selected from C1-6 alkyl, C1-6 haloalkyl, C2-6 alkenyl, C2-6 alkynyl, C3-7 cycloalkyl, C2-7 heterocycloalkyl, phenyl and —(CH2)1-4-phenyl.

### Claim 23 (depends on 22)

The compound of claim 22, wherein R1 is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 heteroalkyl, wherein R1 is substituted with from 0 to 5 RR1 substituents selected from the group consisting of halogen, F, Cl, Br, I, —NRaRb, —SRa, —ORa, —C(O)ORa, —C(O)NRaRb, —C(O)Ra, —NRaC(O)Rb, —OC(O)Rc, —NRaC(O)NRaRb, —OC(O)NRaRb, —NRaS(O)2NRaRb, —S(O)2Ra, —S(O)2NRaRb, —Rc, —NO2, —N3, ═O—CN and X1—Rc1; and R2 is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 heteroalkyl and is substituted with from 0 to 3 RR2 substituents.

### Claim 24 (depends on 23)

The compound of claim 23, wherein R1 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, 2-hydroxyprop-2-yl, butyl, sec-butyl, tert-butyl, isobutyl, pentyl, dimethylaminomethyl and hexyl.

### Claim 25 (depends on 22)

The compound of claim 22, wherein R1 is selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, azetidin-1-yl, azetidin-2-yl, azetidin-3-yl, pyrrolidin-1-yl, pyrrolidin-2-yl, pyrrolidin-3-yl, piperidin-1-yl, piperidin-2-yl, piperidin-3-yl, piperidin-4-yl, oxetan-2-yl, oxetan-3-yl, tetrahydrofuran-2-yl, tetrahydrofuran-3-yl, tetrahydropyran-2-yl, tetrahydropyran-3-yl and tetrahydropyran-4-yl, oxepan-2-yl, oxepan-3-yl, oxepan-4-yl, phenyl, pyrrol-2-yl, pyrrol-3-yl, pyrazol-3-yl, pyrazol-4-yl, pyrazol-5-yl, furan-2-yl, furan-3-yl, thien-2-yl, thien-3-yl, thiazol-2-yl, thiazol-3-yl, thiazol-4-yl, imiazol-1-yl, imidazol-4-yl, pyrid-2-yl, pyrid-3-yl, pyrid-1-yl, pyrimidin-1-yl, pyrimidin-2-yl, pyrimidin-3-yl, pyrazin-2-yl, pyridazin-2-yl, pyridazin-3-yl and triazin-2-yl, wherein R1 is substituted with from 0 to 3 RR1 substituents; and R2 is selected from the group consisting of hydrogen, C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 heteroalkyl and is substituted with from 0 to 3 RR2 substituents.

### Claim 26 (depends on 25)

The compound of claim 25, wherein R1 is selected from the group consisting
of:

### Claim 27 (depends on 25)

The compound of claim 25, wherein R1 is selected from the group set forth in FIG. 1.

### Claim 28 (depends on 23)

The compound of claim 23, wherein R2 is selected from the group consisting of hydrogen,

### Claim 29 (depends on 28)

The compound of claim 28, wherein R2 is selected from the group consisting of hydrogen, methyl, ethyl, propyl, isopropyl, cyclopropylmethyl, and methoxyethyl.

### Claim 30 (depends on 1)

The compound of claim 1, wherein the compound is selected from the group consisting of: 1-ethyl-3-(4-(7-methyl-6-morpholino-7H-purin-2-yl)phenyl)urea; (S)-1-ethyl-3-(4-(7-methyl-6-(3-methylmorpholino)-7H-purin-2-yl)phenyl)urea; (R)-1-ethyl-3-(4-(7-methyl-6-(3-methylmorpholino)-7H-purin-2-yl)phenyl)urea; (S)-1-ethyl-3-(4-(6-(3-ethylmorpholino)-7-methyl-7H-purin-2-yl)phenyl)urea; 1-ethyl-3-(4-(7-methyl-6-(1,4-oxazepan-4-yl)-7H-purin-2-yl)phenyl)urea; (S)-1-ethyl-3-(4-(7-ethyl-6-(3-methylmorpholino)-7H-purin-2-yl)phenyl)urea; (S)-1-(4-(8-butyl-7-methyl-6-(3-methylmorpholino)-7H-purin-2-yl)phenyl)-3-ethylurea; (S)-1-ethyl-3-(4-(8-(2-hydroxypropan-2-yl)-7-methyl-6-(3-methylmorpholino)-7H-purin-2-yl)phenyl)urea; 1-(4-(7-((1S,4S)-2-oxa-5-azabicyclo[2.2.1]heptan-5-yl)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)-3-ethylurea; (S)-1-ethyl-3-(4-(1-methyl-7-(3-methylmorpholino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)urea; (S)-1-ethyl-3-(4-(7-(3-ethylmorpholino)-1-methyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)urea; (S)-1-ethyl-3-(4-(7-(3-ethylmorpholino)-1,3-dimethyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)urea; (S)-1-(4-(1-methyl-7-(3-methylmorpholino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)-3-(oxetan-3-yl)urea; and (S)-1-(4-(1-methyl-7-(3-methylmorpholino)-1H-pyrazolo[4,3-d]pyrimidin-5-yl)phenyl)-3-(2-(methylsulfonyl)ethyl)urea.

### Claim 31

A pharmaceutical composition comprising a compound of Formula I and a pharmaceutically acceptable diluent, carrier or excipient.

### Claim 32

A method of treating a cancer selected from the group consisting of breast, NSCLC, small cell carcinoma, liver carcinoma, lymphoid disorders, sarcoma, colon-rectum, rectum and leukemia in a mammal, said method comprising administering to the mammal a therapeutically effective amount of a compound of Formula I.

### Claim 33 (depends on 1, 32)

The method of claim 32, wherein a compound of claim 1 is administered in combination with another chemotherapeutic agent.

### Claim 34 (depends on 32)

The method of claim 32, wherein said mammal is human.

### Claim 35

Use of a compound of Formula I in the manufacture of a medicament for the treatment of cancer.
